High expression of programmed cell death protein 1 on peripheral blood T‑cell subsets is associated with poor prognosis in metastatic gastric cancer

Shi,Bian; Li,Qiujian; Ma,Xuhui; Gao,Qilong; Li,Lu; Chu,Junfeng

doi:10.3892/ol.2018.9190

High expression of programmed cell death protein 1 on peripheral blood T‑cell subsets is associated with poor prognosis in metastatic gastric cancer

Authors:
- Bian Shi
- Qiujian Li
- Xuhui Ma
- Qilong Gao
- Lu Li
- Junfeng Chu
View Affiliations

Affiliations: Department of Integrated Traditional Chinese and Western Medical Oncology, Zhengzhou University Affiliated Cancer Hospital, Zhengzhou, Henan 450001, P.R. China, Department of Oncology, Zhengzhou University Affiliated Cancer Hospital, Zhengzhou, Henan 450001, P.R. China
Published online on: July 23, 2018 https://doi.org/10.3892/ol.2018.9190
Pages: 4448-4454
Copyright: © Shi et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Immune checkpoints in solid tumors serve important roles in metastasis. The present study was designed to explore the expression of programmed cell death protein 1 (PD‑1) on peripheral blood T‑cell subsets and its role in the clinicopathological features and prognosis of patients with metastatic gastric cancer. The expression of PD‑1 in peripheral blood T‑cell subsets was detected in 100 metastatic gastric cancer patients prior to the first line chemotherapy by flow cytometric analysis. The potential associaton between the peripheral blood T‑cell subsets PD‑1 level and the clinicopathological features of patients with metastatic gastric cancer and the clinical outcomes was analyzed. The percent of high PD‑1 expressed cluster of differentiation (CD)3+, CD3+CD4+ and CD3+CD8+ T‑cells was 20.4, 13.0 and 9.4%, respectively in patients with metastatic gastric cancer. The overall survival (OS) and progression‑free survival (PFS) rate of the 100 patients with metastatic gastric cancer was 12.2 and 3.9 months, respectively. Kaplan‑Meier curve with long‑rank analysis indicated that patients with higher PD‑1+/CD3+, PD‑1+/CD3+CD4+ and PD‑1+/CD3+CD8+ levels had a worse prognosis (all P<0.05). Univariate and multivariate analysis revealed that high PD‑1+/CD3+ [hazard ratio (HR), 2.145; P=0.015], high PD‑1+/CD3+CD4+ (HR, 1.866; P=0.034) and high PD‑1+/CD3+CD8+ (HR, 1.817; P=0.033) level in peripheral blood were independent risk factors for predicting the survival time of patients with metastatic gastric cancer. High PD‑1+/CD3+, high PD‑1+/CD3+CD4+ and high PD‑1+/CD3+CD8+ expression conferred a lower overall survival rate in patients with metastatic gastric cancer. These results suggest that high PD‑1 expression on peripheral blood T‑cell subsets may potentially be novel prognostic biomarker for metastatic gastric cancer.

View Figures

View References

1	Hamamoto Y: Complications in advanced or recurrent gastric cancer patients with peritoneal metastasis during and after palliative systemic chemotherapy. Mol Clin Oncol. 3:539–542. 2015. View Article : Google Scholar : PubMed/NCBI
2	Chen W, Zheng R, Baade PD, Zhang S, Zeng H, Bray F, Jemal A, Yu XQ and He J: Cancer statistics in China, 2015. CA Cancer J Clin. 66:115–132. 2016. View Article : Google Scholar : PubMed/NCBI
3	Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, Parkin DM, Forman D and Bray F: Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN, 2012. Int J Cancer. 136:E359–E386. 2015. View Article : Google Scholar : PubMed/NCBI
4	Price TJ, Shapiro JD, Segelov E, Karapetis CS, Pavlakis N, Van Cutsem E, Shah MA, Kang YK and Tebbutt NC: Management of advanced gastric cancer. Expert Rev Gastroenterol Hepatol. 6:199–209. 2012. View Article : Google Scholar : PubMed/NCBI
5	Topalian SL, Taube JM, Anders RA and Pardoll DM: Mechanism-driven biomarkers to guide immune checkpoint blockade in cancer therapy. Nat Rev Cancer. 16:275–287. 2016. View Article : Google Scholar : PubMed/NCBI
6	Freeman GJ, Long AJ, Iwai Y, Bourque K, Chernova T, Nishimura H, Fitz LJ, Malenkovich N, Okazaki T, Byrne MC, et al: Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation. J Exp Med. 192:1027–1034. 2000. View Article : Google Scholar : PubMed/NCBI
7	Latchman Y, Wood CR, Chernova T, Chaudhary D, Borde M, Chernova I, Iwai Y, Long AJ, Brown JA, Nunes R, et al: PD-L2 is a second ligand for PD-1 and inhibits T cell activation. Nat Immunol. 2:261–268. 2001. View Article : Google Scholar : PubMed/NCBI
8	Zheng H, Liu X, Zhang J, Rice SJ, Wagman M, Kong Y, Zhu L, Zhu J, Joshi M and Belani CP: Expression of PD-1 on CD4+ T cells in peripheral blood associates with poor clinical outcome in non-small cell lung cancer. Oncotarget. 7:56233–56240. 2016. View Article : Google Scholar : PubMed/NCBI
9	Komura T, Sakai Y, Harada K, Kawaguchi K, Takabatake H, Kitagawa H, Wada T, Honda M, Ohta T, Nakanuma Y and Kaneko S: Inflammatory features of pancreatic cancer highlighted by monocytes/macrophages and CD4+ T cells with clinical impact. Cancer Sci. 106:672–686. 2015. View Article : Google Scholar : PubMed/NCBI
10	Shibutani M, Maeda K, Nagahara H, Fukuoka T, Nakao S, Matsutani S, Hirakawa K and Ohira M: The prognostic significance of the tumor-infiltrating programmed cell death-1⁺ to CD8⁺ lymphocyte ratio in patients with colorectal cancer. Anticancer Res. 37:4165–4172. 2017.PubMed/NCBI
11	Baas W, Gershburg S, Dynda D, Delfino K, Robinson K, Nie D, Yearley JH and Alanee S: Immune characterization of the programmed death receptor pathway in high risk prostate cancer. Clin Genitourin Cancer. 15:577–281. 2017. View Article : Google Scholar : PubMed/NCBI
12	Yuan J, Zhang J, Zhu Y, Li N, Tian T, Li Y, Li Y, Li Z, Lai Y, Gao J and Shen L: Programmed death-ligand-1 expression in advanced gastric cancer detected with RNA in situ hybridization and its clinical significance. Oncotarget. 7:39671–39679. 2016. View Article : Google Scholar : PubMed/NCBI
13	Eto S, Yoshikawa K, Nishi M, Higashijima J, Tokunaga T, Nakao T, Kashihara H, Takasu C, Iwata T and Shimada M: Programmed cell death protein 1 expression is an independent prognostic factor in gastric cancer after curative resection. Gastric Cancer. 19:466–471. 2016. View Article : Google Scholar : PubMed/NCBI
14	Vali B, Jones RB, Sakhdari A, Sheth PM, Clayton K, Yue FY, Gyenes G, Wong D, Klein MB, Saeed S, et al: HCV-specific T cells in HCV/HIV co-infection show elevated frequencies of dual Tim-3/PD-1 expression that correlate with liver disease progression. Eur J Immunol. 40:2493–2505. 2010. View Article : Google Scholar : PubMed/NCBI
15	Lauwers GY CF and Graham DY: Curado MP tumours of the stomach. WHO classification of tumours of the digestive system Bosman FT CF. Hruban RH and Theise ND: 48–59. 2010.
16	Aldarouish M and Wang C: Trends and advances in tumor immunology and lung cancer immunotherapy. J Exp Clin Cancer Res. 35:1572016. View Article : Google Scholar : PubMed/NCBI
17	Dougan M and Dranoff G: Immune therapy for cancer. Annu Rev Immunol. 27:83–117. 2009. View Article : Google Scholar : PubMed/NCBI
18	Sharon E, Streicher H, Goncalves P and Chen HX: Immune checkpoint inhibitors in clinical trials. Chin J Cancer. 33:434–444. 2014. View Article : Google Scholar : PubMed/NCBI
19	Ansell SM, Lesokhin AM, Borrello I, Halwani A, Scott EC, Gutierrez M, Schuster SJ, Millenson MM, Cattry D, Freeman GJ, et al: PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma. N Engl J Med. 372:311–319. 2015. View Article : Google Scholar : PubMed/NCBI
20	Brahmer JR, Hammers H and Lipson EJ: Nivolumab: Targeting PD-1 to bolster antitumor immunity. Future Oncol. 11:1307–1326. 2015. View Article : Google Scholar : PubMed/NCBI
21	Muro K, Chung HC, Shankaran V, Geva R, Catenacci D, Gupta S, Eder JP, Golan T, Le DT, Burtness B, et al: Pembrolizumab for patients with PD-L1-positive advanced gastric cancer (KEYNOTE-012): A multicentre, open-label, phase 1b trial. Lancet Oncol. 17:717–726. 2016. View Article : Google Scholar : PubMed/NCBI
22	Rizvi NA, Mazières J, Planchard D, Stinchcombe TE, Dy GK, Antonia SJ, Horn L, Lena H, Minenza E, Mennecier B, et al: Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): A phase 2, single-arm trial. Lancet Oncol. 16:257–265. 2015. View Article : Google Scholar : PubMed/NCBI
23	Böger C, Behrens HM, Mathiak M, Krüger S, Kalthoff H and Röcken C: PD-L1 is an independent prognostic predictor in gastric cancer of Western patients. Oncotarget. 7:24269–24283. 2016. View Article : Google Scholar : PubMed/NCBI
24	Fang W, Chen Y, Sheng J, Zhou T, Zhang Y, Zhan J, Liu L, Huang J, Peng P and Zhang L: Association between PD-L1 expression on tumour-infiltrating lymphocytes and overall survival in patients with gastric cancer. J Cancer. 8:1579–1585. 2017. View Article : Google Scholar : PubMed/NCBI
25	Saito R, Abe H, Kunita A, Yamashita H, Seto Y and Fukayama M: Overexpression and gene amplification of PD-L1 in cancer cells and PD-L1+ immune cells in Epstein-Barr virus-associated gastric cancer: The prognostic implications. Mod Pathol. 30:427–439. 2017. View Article : Google Scholar : PubMed/NCBI
26	Wen T, Wang Z, Li Y, Li Z, Che X, Fan Y, Wang S, Qu J, Yang X, Hou K, et al: A four-factor immunoscore system that predicts clinical outcome for stage II/III gastric cancer. Cancer Immunol Res. 5:524–534. 2017. View Article : Google Scholar : PubMed/NCBI
27	Zhang L, Qiu M, Jin Y, Ji J, Li B, Wang X, Yan S, Xu R and Yang D: Programmed cell death ligand 1 (PD-L1) expression on gastric cancer and its relationship with clinicopathologic factors. Int J Clin Exp Pathol. 8:11084–11091. 2015.PubMed/NCBI
28	Zhang M, Dong Y, Liu H, Wang Y, Zhao S, Xuan Q, Wang Y and Zhang Q: The clinicopathological and prognostic significance of PD-L1 expression in gastric cancer: A meta-analysis of 10 studies with 1,901 patients. Sci Rep. 6:379332016. View Article : Google Scholar : PubMed/NCBI
29	Wu Y, Cao D, Qu L, Cao X, Jia Z, Zhao T, Wang Q and Jiang J: PD-1 and PD-L1 co-expression predicts favorable prognosis in gastric cancer. Oncotarget. 8:64066–64082. 2017.PubMed/NCBI
30	Brown JA, Dorfman DM, Ma FR, Sullivan EL, Munoz O, Wood CR, Greenfield EA and Freeman GJ: Blockade of programmed death-1 ligands on dendritic cells enhances T cell activation and cytokine production. J Immunol. 170:1257–1266. 2003. View Article : Google Scholar : PubMed/NCBI
31	Dong H and Chen L: B7-H1 pathway and its role in the evasion of tumor immunity. J Mol Med (Berl). 81:281–287. 2003. View Article : Google Scholar : PubMed/NCBI
32	Schwarzenbach H, Hoon DS and Pantel K: Cell-free nucleic acids as biomarkers in cancer patients. Nat Rev Cancer. 11:426–437. 2011. View Article : Google Scholar : PubMed/NCBI